Latest gastrointestinal stromal tumor Stories
Confirmatory trials show significantly prolonged survival in patients; drug granted regular approval SILVER SPRING, Md., Jan. 31, 2012 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today granted Gleevec (imatinib) regular approval for use in adult patients following surgical removal of CD117-positive gastrointestinal stromal tumors (GIST). Today's action also highlights an increase in overall patient survival when the drug is taken for 36 months rather than the...
EAST HANOVER, N.J., June 5, 2011 /PRNewswire/ -- Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking Gleevec® (imatinib mesylate)* tablets for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (KIT+ GIST) compared to one year of treatment. These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5....
SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Sutent (sunitinib) to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body (metastatic). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than...
WAYNE, N.J., May 10, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and sunitinib as prior treatments. Regorafenib is an investigational agent and is not...
TUEBINGEN, Germany, April 11, 2011 /PRNewswire/ -- immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial (IMPRINT = IMA901 Multi-Peptide vaccine Randomized INTernational study) with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma. The pivotal Phase III study will evaluate as the primary...
WAYNE, N.J., Feb. 4, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted orphan drug status for the treatment of patients with gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration (FDA). Regorafenib is an investigational agent and is not approved by the FDA, the European Medicines Agency (EMA) or other Health Authorities. "This is an important step in the overall...
NEW YORK, Dec. 2, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the European Commission has approved SUTENT® (sunitinib malate) for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors (NET) with disease progression in adults. Experience with SUTENT as initial treatment is limited in this disease. Pancreatic NET is a rare cancer reported in two to four people per million annually worldwide.(1,2) Sutent is the...
NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Pfizer Inc. announced today the discontinuation of the SUN 1120 Phase 3 trial evaluating SUTENT® (sunitinib malate) in combination with prednisone for men with advanced castration-resistant prostate cancer (CRPC) that had progressed despite treatment with a docetaxel-based chemotherapy regimen. During a scheduled interim analysis, an independent Data Monitoring Committee (DMC) found that the combination of sunitinib with prednisone was...
NEW YORK, Aug. 23 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE :PFE) announced today that the SUN 1087 trial of sunitinib in combination with erlotinib versus erlotinib demonstrated a statistically significant improvement in Progression-Free but not in Overall Survival in patients with previously treated advanced non-small cell lung cancer (NSCLC). Overall survival was the primary endpoint of the study and Progression-Free Survival was a secondary endpoint of the study. No new or...
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. However, the duodenal location is less common. Nowadays, surgery is still the only curative approach for GIST. Numerous procedures can be performed to remove duodenal GIST. Some of these operations are extensive and require difficult reconstruction (like pancreaticoduodenectomy; PD). One of the options is a more limited intervention: segmental duodenectomy (SD). However, few studies have...
